CTOs on the Move


 
Founded in 2013, Aphria is integrating their growing expertise with Health Canada`s new Access to Cannabis for Medical Purposes Regulations (ACMPR) for the medicinal marijuana industry. Possessing greenhouse related growing experience in plant and produce related expertise since 1943, Aphria is positioned to be an industry leader in providing patients with the highest quality medical marijuana. Aphria has developed integrated greenhouse growing solutions specifically focused on quality production of cannabis. With the authorization of quantity scale marijuana growing, Aphria greenhouse operations are a natural fit. Aphria is a licensed producer of Medicinal Marijuana under the Health Canada Regulations. Grown in ...
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.aphria.com
  • 35 McCaul St. Suite 201
    Toronto, ON CAN M5T 1V7
  • Phone: 833.254.4877

Executives

Name Title Contact Details

Funding

Aphria raised $80M on 12/02/2019

Similar Companies

Reliance Health

Reliance Health is a non-profit community mental health center focused on enhancing health through mental wellness.

Imprimis Pharmaceuticals

Imprimis Pharmaceuticals is a pharmaceutical company dedicated to delivering high quality and innovative medicines to physicians and patients at affordable prices. We are pioneering a new commercial pathway in the pharmaceutical industry, using compounding pharmacies for the formulation and distribution of high quality, proprietary formulations that are supported by the clinical experience of physicians and their patients. We are focused on ophthalmology and urology drug therapies; however we also sell other formulations outside of our core ophthalmology and urology therapeutic areas. All of our innovative drug formulations are born from the clinical experience of physician prescribers and pharmacist formulators. We believe our unique business model provides us with the opportunity to address unmet patient needs while delivering safe, near-term and affordable medical solutions to Americans. We have made tremendous progress since the launch of our ophthalmology business and our Go Dropless™ educational campaign in April 2014. Our ophthalmology business is disrupting the billion dollar eye drop market as physicians are adopting Dropless Therapy™ for their patients. We recently announced the availability of our LessDrops™ proprietary topical combination eye drops for post LASIK and other ocular surgeries. During first quarter 2015, we launched our urology business, entering the multi-billion dollar interstitial cystitis (IC) market. In connection with our urology launch, we will commercialize our patented Hep-Lido-A formulation and promote the Defeat IC™ educational campaign focused on medical practitioners and the estimated ten million women and men in the U.S. chronically affected by IC and PBS. We are committed to customer relations, highest quality standards, accessible innovation and solving the unmet needs in the markets we serve. We are delivering on the promise of our unique model and look forward to continuing to serve the needs of our customers with additional novel drug therapies in our product portfolio, and in turn grow our business. Our hope is that through the success of our business we will reduce healthcare costs and provide Americans access to high quality, novel and previously unavailable medicines.

Teva Canada

Teva Canada is a Scarborough, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Advanced Targeting Systems

Advanced Targeting Systems is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Meitheal Pharmaceuticals

Founded in 2017, Meitheal Pharmaceuticals is a privately owned pharmaceutical company focusing on generic injectable products. Headquartered near Chicago, Illinois, Meitheal has an established management team and an aggressive growth strategy. Through global partnerships, our goal is to bring supply to US healthcare providers that demand a reliable, high quality, yet affordable supply of injectables.